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V3To trace the evolutionary patterns underlying evolution of coreceptor use within a host, we studied an HIV-1
transmission pair involving a donor who exclusively harbored CCR5-using (R5) variants throughout his entire
disease course and a recipient who developed CXCR4-using variants. Over time, R5 variants in the donor opti-
mized coreceptor use, which was associated with an increased number of potential N-linked glycosylation
sites (PNGS) and elevated V3 charge in the viral envelope. Interestingly, R5 variants that were transmitted to
the recipient preserved the viral characteristics of this late stage genotype and phenotype. Following a selective
sweep, CXCR4-using variants subsequently emerged in the recipient coinciding with a further increase in the
number of PNGS and V3 charge in the envelope of R5 viruses.
Although described in a single transmission pair, the transmission and subsequent persistence of R5 variants
with late stage characteristics demonstrate the potential for coreceptor use adaptation at the population level.
© 2011 Elsevier Inc. All rights reserved.Introduction
Human Immunodeﬁciency Virus type I (HIV-1) target cell entry is
mediated by the interaction of the viral envelope protein with CD4
and a coreceptor on the target cell surface (Alkhatib et al., 1996; Berson
et al., 1996; Dalgleish et al., 1984; Klatzmann et al., 1984). Themain cor-
eceptors used by HIV-1 in vivo are the chemokine receptors CCR5 and
CXCR4 (De Roda Husman et al., 1999; Deng et al., 1996; Dragic et al.,
1996; Feng et al., 1996).
CCR5-using (R5) viruses predominate in the early stages of HIV-1
infection irrespective of the route of transmission (Casper et al., 2002;
Husson et al., 1995; Keele et al., 2008; Salazar-Gonzalez et al., 2008;
Scarlatti et al., 1993; Van 't Wout et al., 1994) and persist throughout
the course of the disease (Connor et al., 1997; Scarlatti et al., 1997;munology M01-120, Academic
he Netherlands.
uitemaker).
therlands.
rights reserved.Schuitemaker et al., 1992). The biological properties of R5 viruses com-
monly evolve throughout the natural course of infection (Jansson et al.,
1996, 1999; Koning et al., 2003; Kwa et al., 2003; Repits et al., 2005). In-
deed, late stage R5 HIV-1 variants show more rapid replication, higher
cytopathicity and a more efﬁcient use of CCR5; the latter is reﬂected
by a decreased sensitivity to inhibition by CCR5 antagonists and the
ability to use CCR5–CXCR4 chimeric coreceptors (Jansson et al., 1999;
Koning et al., 2003; Kwa et al., 2003; Repits et al., 2005). In the absence
of antiretroviral therapy, about 50% of individuals progress to AIDS in
the sole presence of R5 HIV-1 variants (De Roda Husman et al., 1999;
Jansson et al., 1999; Karlsson et al., 1994a; Koot et al., 1993).
The other 50% of HIV-1 subtype B infected individuals progress to
AIDS in the presence of CXCR4-using variants. The emergence of
CXCR4-using HIV-1 generally precedes a faster CD4+ T cell decline
and accelerated disease progression (Connor et al., 1997; Karlsson et
al., 1994b; Koot et al., 1993, 1996; Schuitemaker et al., 1992). Despite
years of extensive research, the determinants for the emergence of
CXCR4-using variants remain largely unresolved.
The evolution of R5 variants throughout infection and the rare
presence of CXCR4-using variants at a very early stage have raised
the question whether viral characteristics of early stage viruses are
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Fig. 1. CD4 counts and plasma viral load during follow-up of subject 19858 (donor) and subject 19308 (recipient).
71D. Edo-Matas et al. / Virology 422 (2012) 70–80advantageous for transmission. However, it is currently unknown
whether the phenotype of late stage R5 variants can be preserved
upon transmission to a new individual, and up to what level it con-
tributes to shape the viral population in the new host (i.e. efﬁciency of
coreceptor use, emergence of CXCR4-using variants, evolutionary rate
or development of resistance to a neutralizing antibody response).
Here, we studied HIV-1 evolution in a donor–recipient pair in which
the donor harbored only R5 variants during his entire course of infection,
whereas in the recipient CXCR4-using variants eventually emerged. We
compared evolutionary rates and dN/dS ratios based on gp120 envelope
sequences, efﬁciency of CCR5 use, and envelopemolecular characteristics
of longitudinally obtained R5 variants, and in particular from R5 variants
obtained prior and after the transmission event, from both donor and re-
cipient.With the longitudinal analysis of changes in viral phenotype and
envelope molecular characteristics in relation to HIV-1 evolutionary
history in this transmission pair, we attempt to deﬁne the role of viral
factors during transmission and in the evolution of the HIV-1 popula-
tion within a host.
Results
Phylogenetic analysis of env sequences demonstrates HIV-1 transmission
from an HIV-1 infected individual with R5 variants only, to an individual
in whom eventually CXCR4-using HIV-1 variants developed
A Maximum likelihood (ML) phylogenetic tree based on env
gp120 C2–C4 sequences from 103 participants of the ACS merged
with a highly-related but not epidemiologically linked international
reference panel of 148 sequences, revealed well-supported clustering
of subject 19858 and subject 19308 derived sequences (data not
shown). Moreover, sequences from subject 19308 were nested in a
larger cluster of sequences that were exclusively derived from subject
19858 (both clusters supported by bootstrap analysis), suggesting
that direct HIV-1 transmission had occurred from subject 19858
(donor) to subject 19308 (recipient). Interestingly, routine testing
using the MT-2 assay for the presence of CXCR4-using variants in
the donor never yielded a positive test, suggestive of the absence of
CXCR4-using variants, while the recipient tested positive in the MT-
2 test from 3.4 years after seroconversion onwards.
To explore in more detail the HIV-1 evolutionary history in these
two subjects we performed ML as well as Bayesian MCMC analysis of
the two subject's viral env sequences. The ML tree (Supplementary
Fig. A1A) and the Bayesian maximum clade credibility (MCC) tree
(Fig. 2A) topologies for the alignment of env gp120 C1–V5 sequences
derived from clonal HIV-1 variants supported a single transmission
event from donor to recipient, showing a temporal structure of se-
quences and monophyletic clustering of the recipient sequences,
which branched off from late donor sequences. Moreover, the phyloge-
nies also demonstrated monophyletic clustering of the recipient'sCXCR4-using variant sequences, which descended from his R5 variants.
The ML tree (Supplementary Fig. A1B) and Bayesian MCC tree (Fig. 2B)
topologies for the shorter alignment of env gp120 C2–C4 sequences de-
rived from clonal HIV-1 variants and viral RNA in serum also showed a
temporal structure of sequences. However in these trees, recipient se-
quences did not cluster monophyletically, as single donor sequences
(three in ML tree, ﬁve in MCMC tree) from later time points fell within
the recipient's cluster. Additionally, themajority of sequenceswith pre-
dicted and/or in vitro tested CXCR4 use of the recipient were part of a
main CXCR4-using sequence cluster but three of them constituted a
separate cluster. Interestingly, these three sequences were derived
from serum at 10 or 2 months before the estimated date of emergence
of CXCR4-using variants and provided discordant results by the V3 cor-
eceptor prediction methods. This may imply that these viral variants
from serumwere intermediates between CCR5- and CXCR4-using viruses
that failed to produce replication-competent progeny. This was further
supported by the absence of viral descendants from these three virus var-
iants. In conclusion, analysis of env gp120 C1–V5 sequences derived from
clonal HIV-1 variants, the most informative alignment, clearly supports a
single transmission event from donor to recipient. Due to lower evolu-
tionary information, the shorter alignment of env gp120 C2–C4 sequences
derived from clonal HIV-1 variants and viral RNA in serum did not yield
accurate reconstructions of the phylogenetic relationships. However,
the clustering of donor sequences from late time points with recipient se-
quences from early time points further underscores the high sequence
similarity between viral populations isolated from donor and recipient,
and hence their close genetic relationship. Differences between se-
quences obtained from RNA in serum and from isolated clonal HIV-1 var-
iants from PBMC could be attributed to the amount of sequence
information rather than to the source from which sequences were
obtained. Therefore, env gp120 C1–V5 sequences from clonal HIV-1 vari-
ants were used for subsequent analysis as this allowed the study of bio-
logical properties of the virus in the context of the original genetic
background.
Bayesian MCMC analysis based on env gp120 C1–V5 sequences from
clonalHIV-1 variants estimated time to themost recent commonancestor
(TMRCA) of the recipient at 98 (95% credible intervals (CI)=93.9–99.8)
months after SC of thedonor. This estimate dates the TMRCA for the recip-
ient, which puts a lower bound on date of HIV-1 transmission, back to
around 12 July 1991, which corresponds to the SC date of the recipient
(14 July 1991). Despite the absence of epidemiological data conﬁrming
the relationship between those two individuals, this strongly supports
the transmission of HIV-1 between the two individuals, as was concluded
from the phylogenetic analysis.
Evolutionary rate of HIV-1 variants from donor and recipient
The mean evolutionary rate in the HIV-1 transmission chain was
estimated to be 0.00012 (95% CI=0.0009–0.0015) substitutions per
72 D. Edo-Matas et al. / Virology 422 (2012) 70–80site per month for the env gp120 C1–V5 sequences from clonal HIV-1
variants, but the coefﬁcient of variation (0.44 (95% CI=0.22–0.71)) in-
dicated considerable rate variation among branches, which justiﬁes the
use of a relaxed clock for the transmission history. To assess whether
evolutionary rates were different between HIV-1 variants in the donor
and in the recipient,weperformedBayesianMCMCanalysis of the clonal
HIV-1 variant sequences for each subject separately. For the recipient,
we also performed an additional analysis solely on the clonal R5 variant
sequences. Bayes factor testing indicated that a strict clock provided a
good ﬁt for the donor, but a relaxed clock appeared to be more appropri-
ate for the recipient (for all clonal HIV-1 variant sequences aswell as clon-
al R5 variant sequences separately, data not shown). For both the relaxed
and strict clock estimates (Fig. 3), the mean evolutionary rate of the
donor's R5 variant sequences was 1.6-fold lower than the estimated evo-
lutionary rate of the recipient's R5 and CXCR4-using variant sequences.
However, the differences were less pronounced when the mean evolu-
tionary rate of the donor's R5 variant sequences was compared to the
mean evolutionary rate of the recipient's R5 variant sequences (1.4 and
1.3-fold difference for relaxed and strict clock estimates, respectively)
and credible intervals were even more broadly overlapping.Fig. 2. Maximum clade credibility trees summarizing the Bayesian MCMC analysis of the he
from clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC). B: Th
from PBMC and env gp120 C2–C4 sequences generated from viral RNA isolated from serum.
of the recipient; light gray: clonal CXCR4-using variants from the recipient. Numbers
seroconversion.Estimation of dN/dS ratios of HIV-1 variants from donor and recipient
To estimate dN/dS ratios, three different models were ﬁtted to the
alignment of donor and recipient env gp120 C1–V5 sequences derived
from clonal HIV-1 variants: Model A (a single dN/dS ratio for all
branches), Model B (separate dN/dS ratios for branches in the donor
and recipient clade) and Model C (separate dN/dS ratios for branches
in the donor clade, in the recipient R5 variant clade and in the recip-
ient CXCR4-using variant clade) (Table 2). Likelihood ratio testing
revealed that Model B provided a signiﬁcantly better ﬁt to the data
than the simpler single ratio model (Model B, p=0.012, and that
Model C did not provide any improvement in ﬁt respect to Model 2,
p=0.391). Although dN/dS ratios for both subjects were b1 under
Model B, indicating a predominantly negatively selection, the higher
dN/dS ratio in the recipient compared to the donor may be attributed
to a more neutral evolution in general or a bout of positive selection
in the viral evolutionary history in this subject. Given that Model 3
did not lead to a better ﬁt, we cannot conclude any difference in
dN/dS between R5 and CXCR4-using sequence clades and that selec-
tion pressure on the CXCR4-using viral population, althoughterochronous env sequences. A: The tree includes env gp120 C1–V5 sequences derived
e tree includes env gp120 C2–C4 sequences derived from clonal HIV-1 variants isolated
Black: clonal R5 variant sequences of the donor; dark gray: clonal R5 variant sequences
represent posterior probabilities. A time scale in months is indicated below. SC:
Fig. 2 (continued).
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Fig. 3.Mean evolutionary rate estimates of clonal HIV-1 variants from donor and recip-
ient. Bayesian MCMC analysis was performed on the env gp120 C1–V5 sequences from
clonal HIV-1 variants from donor (D(R5)), from clonal HIV-1 variants from recipient (R
(R5+X4)) and from clonal R5 variants from recipient (R(R5)), separately, under both
relaxed and strict clock. R5: clonal R5 variants; X4: clonal CXCR4-using variants. Mean
evolutionary rate estimates (nucleotides substitutions per site per month) and 95%
credible intervals are shown.
74 D. Edo-Matas et al. / Virology 422 (2012) 70–80contributing to the overall dN/dS ratio for the recipient, is not solely
responsible for the differences with the dN/dS ratio of the donor.
To examine inmore detail the differences observed in dN/dS ratio es-
timates between donor and recipient, we estimated the branch lengths
of the MCC tree based on env gp120 C1–V5 sequences from clonal
HIV-1 variants in expected synonymous (E[S]) and nonsynonymous (E
[N]) changes. For this we used a codon model that allows for a different
synonymous and nonsynonymous substitution rate along each branch
(a ‘local’ codon model, (Kosakovsky Pond et al., 2009)) (Supplementary
Figs. A2 A and B). We subsequently plotted E[S] and E[N] divergence
over time in Fig. 4. In general, E[S] and E[N] variation occurred roughly
at similar pace, as reﬂected in the parallel increase in E[S] and E[N] dur-
ing the entire follow-up of the donor, and during the follow-up after the
second time point of the recipient. However, a marked increase in E[N]
could be observed between the ﬁrst and second sampling time point
of the recipient (101 and 126.6 months since SC of the donor,Table 1
Study subjects, time points, number of sequences analyzed and number of clonal HIV-1 var
Cohort
ID
Subject Sampling
time after
SC or imputed
SC date*
(months)
Time to X4
emergencea
(months)
Time sinc
of the don
(months)
19858 Donor 40*
66*
90*
111*
19308 Recipient 3 −36 101
8 −31 105
26 −13 124
28.8 −10.2 126.6
29.4 −9.6 127.2
37 −2 134
41 2 139
50 11 148
53 14 151
59 20 156
R5: predicted and/or in vitro tested CCR5 use.
X4: predicted and/or in vitro tested CXCR4 use.
a Time to emergence of CXCR4-using viruses (X4) (estimated date between last negative
b Number of clonal HIV-1 variants tested for sensitivity to anti-CCR5 monoclonal antibodrespectively) and, in fact, between these points E[N] divergence
exceeded E[S] divergence. This is a clear signal for a selective sweep be-
tween these time points, in other words, it indicates that during that
time frame viral envelopes of the recipient were subject to positive se-
lection. The E[N] and E[s] trees also show that while there is a long
branch between these time points in the E[N] tree, there is hardly any di-
vergence in the E[S] tree. This suggests that the increase in E[N] between
the ﬁrst two timepoints of the recipient is responsible for the higher dN/
dS in the donor as compared to the recipient. The fact that this positive
selection is restricted to the time between these time points explains
why the evolutionary rate is only moderately faster in general between
donor and recipient and why dN/dS is not particularly higher for the
CXCR4-using variants.CCR5 use of R5 variants from donor and recipient
In order to determine the efﬁciency of CCR5 use of R5 variants, before
and after transmission, we tested the sensitivity of longitudinally
obtained R5 variants from donor and recipient to inhibition by two
anti-CCR5 monoclonal antibodies directed against the CCR5 N-terminal
domain (MAb RoAb13) and the second extracellular loop (ECL2) of
CCR5 (MAb RoAb952). Aminimum of two and amaximum of six R5 var-
iants per time point were tested (Table 1).
R5 variants from the donor showed an increasing resistance to MAb
RoAb13-mediated inhibition overtime (Fig. 5A), as shown by a signiﬁ-
cant increase in IC50 values per time point (P=0.012), but not to MAb
RoAb952-mediated inhibition (Fig. 5B). However, we did observe a
trend towards higher IC50 values of MAb RoAb952 for R5 variants from
the later time point (111 months after SC; average IC50 (ng/ml)=
850.8±724.8) as compared to R5 variants isolated at earlier time points
((40, 66 and 90 months after SC; average IC50 (ng/ml)=138±102.3);
P=0.0685).
A decrease in IC50 values between R5 variants isolated at the ﬁrst
time point and at later time points from the recipient was observed
for the two anti CCR5MAbs (Figs. 5A and B), although these differences
did not approach statistical signiﬁcance.
R5 variants fromdonor and recipient isolated close to the transmission
event showed a similar sensitivity to inhibition by the twoMAbs (Figs. 5A
and B), as there were no signiﬁcant differences between IC50s of the ear-
liest R5 variants from the recipient and IC50s of R5 variants isolated from
the donor prior (90 months after SC) and after (111 months after SC) theiants tested for sensitivity to anti-CCR5 monoclonal antibodies.
e SC
or
Serum Clonal HIV-1 variants
Nr. of
sequences
Nr. of
sequences
Sensitivity to anti-CCR5
antibodiesb
R5 X4 R5 X4 R5
2 6 4
5 5 3
5 4 5
4 6 4
na na 6 0 5
13 0 na na na
13 0 na na na
na na 4 0 2
10 2 na na na
12 2 na na na
9 5 8 7 5
5 7 na na na
4 12 4 11 4
11 4 na na na
and ﬁrst positive MT-2 test).
ies.
Table 2
dN/dS estimates.
Model Branch set dN/
dS
Likelihood LRTa
comparison Δ and p
Model A D and R (R5+X4) 0.67 −5017.9
Model B D 0.54 −5014.7 Model A vs Model B 6.37 (p=0.012)
R (R5+X4) 0.88
Model C D 0.54 −5014.3 Model A vs Model B 0.74 (p=0.391)
R (R5) 0.82
R (X4) 1.12
D: donor; R: recipient; R5: branches for clonal R5 variant sequences; X4: branches for clonal CXCR4-using variant sequences; dN/dS: non-synonymous/synonymous rates ratio;Δ represents
twice the log likelihood difference between the simple andmore complexmodel and p represents the probability that Δwould be obtained under the simplemodel (for 1 df, the chi-square
cut-off is 3.84 at the 0.05 signiﬁcance level).
a Likelihood ratio test.
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these variants used CCR5 with the same efﬁciency.
Envelope molecular properties of HIV-1 variants from donor
and recipient
Variation in charge and PSSM score of the env gp120 V3 region and
in the number of Potential N-linked Glycosylation Sites (PNGS) of the
env gp120 C1–V5 region were studied, over the course of infection, for
R5 variants from the donor and for R5 and CXCR4-using variants from
the recipient.
The charge of the V3 regions for R5 variants from both donor and re-
cipient increased over time (P=0.03 and P=0.032 respectively;
Fig. 6A) but was always lower than for CXCR4-using variants of the re-
cipient. Whereas no change in PSSM score was observed for R5 variants
from the donor, PSSM score for the R5 variants from the recipient signif-
icantly increased over time (Pb0.0001; Fig. 6B). R5 variants isolated at
the last three time points from the recipient had overall more positively
charged V3 regions and higher PSSM score than R5 variants from the
donor (Pb0.0001 in both cases).
An overall increase in number of PNGS over time was observed in R5
variants of both patients (P=0.031 and P=0.002 respectively; Fig. 6C).
For R5 variants of the recipient, this increase was more pronounced,
reaching the maximum peak at the second time point, after which a de-
crease in number of PNGS was observed in both R5 and CXCR4-using
variants.
The V3 charge for the earliest R5 variants from the recipient was
similar to the V3 charge for the R5 variants isolated from the donorFig. 4. Root-to-tip divergence based on MCC branch lengths estimated in expected
Nonsynonymous (E[N]) and Synonymous Substitutions (E[s]) for clonal HIV-1 variants
from donor and recipient. White-ﬁlled symbols and black lines represent donor diver-
gences whereas gray-ﬁlled symbols and gray lines represent the recipient divergences.
Lines represent moving averages for E[S] (dotted lines) and E[N] (full lines).prior (90 months after SC) and after (111 months after SC) the trans-
mission. The PSSM score between the earliest R5 variants from the re-
cipient and the R5 variants from the donor isolated prior (90 months
after SC) transmission was similar, but the PSSM score of the R5 var-
iants isolated from the donor isolated after (111 months after SC)
transmission was signiﬁcantly higher than for the earliest R5 variants
of the recipient. Moreover, the number of PNGS was also similar for the
earliest R5 variants from the recipient and the geneticallymost related R5
variants from the donor, which according to the phylogenetic analysis
(Fig. 2A and Supplementary Fig. A1A), were the variants isolated after
the transmission (111 months after SC). However, the number of PNGS
of the earliest R5variants from the recipientwas lower than inR5 variants
isolated from the donor prior the transmission event (90 months after
SC).
Discussion
AnHIV-1 transmission pair provided the unique opportunity to study
in detail the evolution of highly related HIV-1 variants in two unrelated
host environments after transmission fromone individual, who only har-
bored R5 variants during his entire disease course, to another individual
in whom CXCR4-using variants emerged after a 3.4 year-period during
which only R5 variants were detected. Phylogenetic analysis supported
a single transmission of R5 variants from donor to recipient and revealed
that CXCR4-using variants that emerged in the recipient descended from
the transmitted and initially expanded R5 viral population. This data im-
plies that CXCR4-using variants can indeed emerge “denovo” and are not
necessarily acquired by transmission.
An increase in efﬁciency of HIV-1 CCR5 use was observed over time
in the donor. Interestingly, the earliest recipient's R5 variants displayed
a similar efﬁciency of CCR5 use as these late R5 variants from the donor,
which were isolated close to the moment of transmission, and main-
tained this late-stage phenotype during follow-up. At similar time
points in the course of infection, CD4+ T cell counts and viral load
(VL) were respectively lower and higher in the recipient as compared
to the donor (Fig. 1). The lower CD4+ T cell counts, and thus the
lower amount of target cells in the recipient may have facilitated the
persistence of R5 variants with highly efﬁcient CCR5 use after transmis-
sion, by itself giving rise to high VL. Alternatively or in addition, the
lower CD4+ T cell counts and, consequently, the lower target cell avail-
ability already from the beginning of the infection, could at least partial-
ly explain the initially stronger selection pressure on HIV-1 in the
recipient. Indeed, although selection pressure on the HIV-1 envelope
was roughly similar in donor and recipient, a stronger positive selection
pressure was observed on viruses of the recipient during the 2.4 years
immediately after transmission, which was reﬂected in an overall
higher ratio of nonsynonymous versus synonymous substitution rates
(dN/dS). This explains why the viral evolutionary rate, which is deter-
mined by the viral mutation rate, the viral generation time, and the se-
lective pressure acting on the virus, is only moderately faster in the
recipient than in the donor.
Fig. 5. Susceptibility to anti-CCR5 monoclonal antibodies mediated inhibition of longitudinally obtained clonal R5 variants from donor and recipient. Geomean IC50 values and standard
error of the mean per time point are shown. aP-value for Kruskal–Wallis test for donor. A: susceptibility to RoAb13 monoclonal antibody; B: susceptibility to RoAb952 monoclonal
antibody; IC50: 50% inhibitory concentration; SC: seroconversion.
76 D. Edo-Matas et al. / Virology 422 (2012) 70–80Given the high mutation rate of HIV-1, and considering that few
amino acid changes in the envelope V3 region are sufﬁcient for a switch
from CCR5 to CXCR4 coreceptor use (Chesebro et al., 1996; Cordonnier
et al., 1989; De Jong et al., 1992; Harrowe and Cheng-Mayer, 1995;
Mosier et al., 1999; Shimizu et al., 1999; Shioda et al., 1992), emergence
of CXCR4-using variants—if beneﬁcial for the virus—would be expected
to occur rapidly and relatively early in the course of infection in every
patient. However, absence of CXCR4-using variants during the entire
disease course is rather common (Koot et al., 1993, 1999), and when
CXCR4-using variants do emerge, this generally occurs at a late stage
of disease. The lower replication rate, reduced efﬁciency of coreceptor
use and higher susceptibility to neutralizing antibodies (Kuiken et al.,
1992; Pastore et al., 2004; Van 't Wout et al., 1998) of variants that are
in transition fromCCR5 to CXCR4 use suggest that intermediate variants
traverse a stage of reduced viral ﬁtness. Therefore, additional compen-
satory mutations, which most likely are context dependent, may be re-
quired to create the background in which the essential V3 region
mutations result in a successfully replicating CXCR4-using HIV-1 vari-
ant. In our study, the transmitted R5 variants, as a result of adaptation
to the donor's environment, may have had already a backbone with
part of the mutations required for the transition to a CXCR4-using phe-
notype. Indeed, the gp120 envelope V3 regions of late R5 variants from
the recipient were overall more positively charged than of R5 variants
from the donor and had higher PSSM scores. The fact that the V3 region
of a CXCR4-using envelope is generally more positively charged (De
Jong et al., 1992; Fouchier et al., 1992, 1995; Shioda et al., 1992) and
has a higher PSSM score (Jensen et al., 2003) may indicate that the en-
velope composition of the recipient's R5 viruses may have been more
similar to the one of a CXCR4-using virus. The complete absence of
CXCR4-using variants in the donor despite sufﬁcient follow-up timeFig. 6. Envelope molecular properties from viral populations from donor and recipient dur
region; B: average PSSM score and standard error of the mean of the gp120 V3 region; C:
for Kruskal–Wallis test for donor; bP-values for Kruskal–Wallis test for recipient; *Mann–W(5 years after the transmission event and 4 years after the last time
point studied in the donor), implies that host factors are likely to play
a role in the acquisition of CXCR4 use. Indeed, host factors such as cor-
eceptor and IL-7 expression levels have previously been recognized as
determinants in the evolution towards CXCR4 use (Brieu et al., 2011;
van Rij et al., 2003). Moreover, the higher incidence of CXCR4-using
HIV-1 variants when CD4+ T cell counts drop below 500 cells/μl (Koot
et al., 1999) suggests that host immune surveillance may counteract
the development of these viruses. The higher CD4+ T cell counts in
the donor may therefore correlate with the absence of CXCR4-using
variants in this patient. The actual host factors involved in the differen-
tial viral evolution in the partners of this particular transmission pair re-
main to be established.
The initial increase in PNGS in the viral envelope sequences was
more pronounced in the R5 variants from the recipient than from the
donor, andmay reﬂect the continuous viral escape from the autologous
humoral immune response in the host (Bunnik et al., 2008; Cao et al.,
1997; Cheng-Mayer et al., 1999; Sagar et al., 2006; Saunders et al.,
2005; van Gils et al., 2010, 2011; Wei et al., 2003). In line, serum from
the recipient, but not the donor, had cross-reactive neutralizing activity
(CrNA) (Euler et al., 2010 and submitted for publication). The emer-
gence of CXCR4-using variants in the recipient coincides with a decline
in CrNA (Euler et al., 2010) and a decrease in PNGS in both R5 and
CXCR4-using variants. The decline in humoral immunity could be a
sign of the impairment of the immune system, which, as discussed be-
fore, might be one of the factors favoring the emergence of CXCR4-
using variants.
We show that recently transmittedR5HIV-1 variants canhave similar
envelopemolecular properties and efﬁciency of CCR5 use as late stage R5
variants. In agreement, VL set-point has recently been shown to be ining disease course. A: Average charge and standard error of the mean of the gp120 V3
average number of PNGS and standard error of the mean in gp120 C1–V5; aP-values
ithney U test; SC: seroconversion.
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has been shown at the population level (Alizon et al., 2010). This implies
that late stage adaptations that support virus replication, efﬁcient target
cell infection and evasion from the host immune response can be pre-
served upon transmission, which may contribute to the evolution of
HIV-1 phenotype and the rise in VL set-point throughout the HIV-1 ep-
idemic (Bunnik et al., 2010; Gras et al., 2009; Kawashima et al., 2009;
van Manen et al., 2011). However, the increased risk of transmission
in the acute phase relative to the chronic phase of infection, which
plays a pivotal role in HIV-1 spread (Jacquez et al., 1994; Koopman et
al., 1997; Leynaert et al., 1998; Pao et al., 2005; Pilcher et al., 2004;
Yerly et al., 2001), could explain why the adaptation of HIV-1 at the
population level seems to be a slow process.
Although focused on a single transmission case,wehave shownhere
that a late stage viral phenotype and envelopemolecular properties can
be transmitted and preserved in the recipient. In-depth studies on HIV-
1 transmission chainsmay advance our understanding of the evolution-
ary dynamics of HIV-1molecular and biological propertieswithin a host
and at the population level throughout the epidemic history.
Material and methods
Study subjects and samples
Longitudinal cryopreserved peripheral blood mononuclear cells
(PBMC) samples from two homosexual men, subject 19858 (donor)
and subject 19308 (recipient), who participated in the Amsterdam
Cohort Studies on HIV-1 infection and AIDS (ACS, http://www.
amsterdamcohortstudies.org), with an imputed or documented sero-
conversion (SC) date (Geskus, 2000), respectively, were used for this
study. The donor remained therapy-naïve while the recipient received
changing antiretroviral therapy (AZT+3TC; ddI+d4T+Indinavir)
starting at the third-before-last time point analyzed (50 months after
SC). Time points studied are shown in Table 1. Longitudinal data on
CD4+ T cell counts and plasma viral load are shown in Fig. 1.
The Amsterdam Cohort Studies are conducted in accordance with
the ethical principles set out in the declaration of Helsinki and were
approved by the Academic Medical Center institutional medical
ethics committee. Written informed consent was obtained from all
cohort participants.
Isolation of replication-competent clonal HIV-1 variants from PBMC
Replication-competent clonal HIV-1 variants were isolated by co-
cultivation of serial dilutions of cryopreserved patient PBMC with
PHA-stimulated PBMC from HIV-1 seronegative donors as described
previously (Schuitemaker et al., 1992; Van 't Wout et al., 2008).
From each time point, a median of 6 clonal HIV-1 variants (range,
4–15) was subjected to DNA isolation, PCR and sequencing (Table 1).
DNA isolation, PCR and env gp120 C1–V5 sequencing from replication-
competent clonal HIV-1 variants from PBMC
Total DNAwas isolated from 0.5–1×106 HIV-1 infected cells using a
modiﬁcation of the L6 isolation method (Kootstra and Schuitemaker,
1999). Gp120 env PCR ampliﬁcation was performed with one outer
PCR with primers TB3 forward (5′-GGCCTTATTAGGACACATAGT-
TAGCC-3′) and OFM19 reverse (5′-GCACTCAAGGCAAGCTTTATT-
GAGGCTTA-3′) and a nested PCR with primers env1aTOPO forward
(5′-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3′) and envN re-
verse (5′-CTGCTAATCAGGGAAGTAGCCTTGTGT-3′) using the Expand
High Fidelity Taq Polymerase kit (Roche) and the following ampliﬁca-
tion cycles: 2 min 30 s 94 °C, 9 cycles of 15 s 94 °C, 45 s 50 °C, 6 min
68 °C, 30 cycles of 15 s 94 °C, 45 s 53 °C, 6 min 68 °C, followed by
10 min at 68 °C and cooling to 4 °C. PCR products were puriﬁed using
ExoSAP-IT (USB) according to the manufacturer's protocol. Sequencingconditions were 5 min at 94 °C, 30 cycles of 15 s at 94 °C, 10 s at 50 °C,
2 min at 60 °C and 10 min at 60 °C. Sequencing of gp120 C1–V5 region
corresponding to HXB2 nucleotide positions 6465 to 7636 was per-
formed using BigDye Terminator v1.1 Cycle Sequencing kit (ABI Prism,
Applied Biosystems) according to the manufacturer's protocol using
the primers Seq1 forward (5′-TACATAATGTTTGGGCCACACATGCC-3′),
Seq4 reverse (5′-CTTGTATTGTTGTTGGGTCTTGTAC-3′), Seq5 forward
(5′-GTCAACTCAACTGCTGTTAAATGGC-3′) and Seq2 reverse (5′-TCCTT-
CATATCTCCTCCTCCAGGTC-3′). Sequences were analyzed on the 3130
xl Genetic Analyzer (Applied Biosystems).
RNA isolation from serum, RT-PCR, PCR ampliﬁcation, molecular cloning
of multiple PCR products and sequencing of env gp120 C2–C4
Env gp120 C2–C4 sequences from viral RNA in serum from donor
and recipient were available from earlier studies (Rachinger et al.,
2010, 2011). HIV-1 RNA isolation from serum samples, cDNA synthe-
sis, molecular cloning of multiple PCR products and sequencing of env
gp120 C2–C4 PCR products (549 nucleotides, corresponding to HXB2
envelope nucleotide positions 811–1290) was performed as de-
scribed previously (Rachinger et al., 2010). From each time point a
median of 3 C2–C4 env (range, 1–5) PCR products was generated
and cloned. A median of 13 env gp120 C2–C4 env (range, 2–16) se-
quences was generated per time point (Table 1).
Prediction and determination of coreceptor use
The two study participants were routinely tested at approximately
3-monthly intervals for the presence of replication-competent CXCR4-
using HIV-1 variants in PBMC using the MT-2 assay (Koot et al., 1992).
CCR5 and CXCR4 coreceptor use of replication-competent clonal
HIV-1 variants at the time points under study was determined by test-
ing the ability of the virus to replicate in MT-2 cells (Van 't Wout et al.,
2008), U87.CD4.CCR5 cells, and U87.CD4.CXCR4 cells, as described pre-
viously (De Roda Husman et al., 1999). V3 sequence based prediction
tools (Position Speciﬁc Scoring Matrix (PSSMNSI/SI)) (Jensen et al.,
2003) and the geno2pheno coreceptor method (FPR=5%) (Sing et
al., 2007) were used to conﬁrm the coreceptor use of the replication-
competent clonal HIV-1 variants and to predict coreceptor use of
sequences derived from viral RNA in serum.
Phylogenetic and molecular clock analysis
Nucleotide sequences were aligned using ClustalW (BioEdit
v.7.0.9, Hall, 1999) and edited manually.
AMaximum Likelihood (ML) tree was reconstructed from published
and unpublished env gp120 C2–C4 sequences from ACS participants,
merged with an international panel of highly related, but not epidemio-
logically linked sequences (downloaded from the Los Alamos database).
Thebest-ﬁt nucleotide substitutionmodel (TVM+I+G), selected byhi-
erarchical likelihood tests (hLRTs, Modeltest v3.7, Posada and Crandall,
1998) was implemented in the heuristic search for the best ML tree ap-
plyingNNI (nearest-neighbor-interchange) branch-swapping algorithm
using PAUP*4.0 (Wilgenbusch and Swofford, 2003), starting with a
Neighbor-Joining (NJ) tree constructed under the Hasegawa–Kishino–
Yano (HKY85)model of evolution (Hasegawa et al., 1985). The resulting
ML tree was rooted with the earliest sequence available and displayed
with Dendroscope (Huson et al., 2007). Statistical support for nodes
was generated using NJ bootstrapping (1000 repeats).
Subsequently, ML and Bayesian MCMC analysis were performed on
the alignment of env gp120 C1–V5 sequences derived from clonal HIV-
1 variants from donor and recipient, and on a set of env gp120 C2–C4 se-
quences derived from viral RNA in serum aligned to the clonal HIV-1
variants but trimmed to the length of the C2–C4 region. ML phylogenies
were reconstructed using PAUP*, applying the best-ﬁt nucleotide substi-
tution model and the TBR (tree-bisection-reconnection) branch-
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the earliest time point from the donor. Bayesian phylogenetic recon-
struction was performed using Markov Chain Monte Carlo (MCMC)
analysis implemented in BEAST v1.5.4 (Drummond and Rambaut,
2007). BEAST focuses on rooted, time-measured phylogenetic trees
with a coalescent prior. We applied a general time-reversible (GTR)
model of nucleotide substitution with gamma-distributed rate variation
among sites, a lognormal relaxed clock model (Drummond et al., 2006)
and a ﬂexible Bayesian skyride tree prior (Minin et al., 2008). MCMC
chains were run sufﬁciently long (100 million generations) to ensure
stationarity and adequate effective sample sizes as diagnosed using
Tracer (http://tree.bio.ed.ac.uk/software/tracer/). Maximum clade cred-
ibility (MCC) trees were annotated using TreeAnotator and visualized
with FigTree (http://tree.bio.ed.ac.uk/software/ﬁgtree/).
To compare evolutionary rates of viruses between donor and recipi-
ent, BayesianMCMC analysis was performed on the env gp120 C1–V5 se-
quences from clonal HIV-1 variants for each patient separately. For the
recipient, an additional analysis was performed solely on the clonal R5
variants sequences. BEAST MCMC analyses were run applying both a
strict and a lognormal relaxed clock model and using the same substitu-
tions models as mentioned above (chain length 200 million); models
were compared using Bayes factor testing (Suchard et al., 2003).
Selective pressure analysis
To quantify the differences in selective pressure between HIV-1
variants from donor and recipient, and between the R5 and CXCR4-
using variants within the recipient, we estimated synonymous/non-
synonymous substitution rate ratios (dN/dS) using codon substitution
models implemented in the codeml program from the PAML package
(Goldman and Yang, 1994; Yang, 1997). Speciﬁcally, we ﬁtted different
models that allow dN/dS to vary among lineages (Yang, 1998). Our
comparison included a model that assumes a single dN/dS for lineages
from donor and recipient (Model A), a model that speciﬁes a different
dN/dS for donor and recipient (Model B) and a model that allows a dif-
ferent dN/dS for the donor, the recipient's R5 variant clade and the reci-
pient's CXCR4-using variant clade (Model C). Analyses were performed
on env gp120 C1–V5 sequences derived from clonal HIV-1 variants and
nested models were compared using the likelihood ratio test (Yang,
1998).
To investigate the accumulation of synonymous and non-
synonymous substitutions over time, we also estimated branch lengths
for the MCC phylogeny of donor and recipient based on env gp120 C1–
V5 clonal HIV-1 variant sequences in expected synonymous (E[S]) and
nonsynonymous (E[N]) substitutions using a local codon model imple-
mented in HyPhy (Kosakovsky Pond et al., 2009; Pond et al., 2005). We
subsequently plotted E[S] and E[N] root-to-tip divergences using Path-
o-gen (http://tree.bio.ed.ac.uk/software/pathogen/).
Sensitivity of HIV-1 to anti-CCR5 monoclonal antibodies mediated
inhibition in a PBMC-based assay
PBMC from 3 to 4 different healthy seronegative blood donors
were isolated by Ficoll-Isopaque density gradient centrifugation and
stimulated for 3 days in Iscove's Modiﬁed Dulbecco's Medium
(IMDM, Lonza) supplementedwith 10% fetal calf serum (FCS; Hyclone),
1 μg/ml phytohemaglutinin (PHA;Welcome), 100 U/ml penicillin and
100 μg/ml streptomycin (Pen/Strep;Gibco Brl), 5 μg/ml Ciproxin
(Bayer) in a culture ﬂask at a cell density of 5×106/ml. In a 96-well
tissue culture plate, a ﬁnal inoculum of 35 TCID50 (50% tissue culture in-
fectious dose) was used to infect 1×105 PHA-stimulated PBMC previ-
ously incubated for 1 h at 37 °C with threefold serial dilutions of
monoclonal antibody (MAb) RoAb13 or RoAb952 (highest concentra-
tion=30 μg/ml) (Ji et al., 2007), kindly provided by Dr. Andreas Jeckle
(Roche). Cultures were incubated for 1 week at 37 °C and 10% CO2. A
median of 5 clonal HIV-1 variants (range, 2–6) were tested per timepoint (Table 1); each clonal HIV-1 variant was tested in triplicate. On
day 7, a third of the culture was transferred to a new plate containing
1×105 new PHA-stimulated PBMCperwell. Virus production in culture
supernatants at days 7 and 11 was analyzed using an in-house p24 an-
tigen capture enzyme-linked immunosorbent assay (ELISA) (Tersmette
et al., 1989). The percent inhibition was calculated by determining the
reduction in p24 production in the presence of the antibody as com-
pared to the cultures that lacked antibody. 50% inhibitory concentra-
tions (IC50) were determined by linear regression.
Analysis of envelope molecular properties
Potential N-linked Glycosylation Sites (PNGS) were identiﬁed using
N-Glycosite (Zhang et al., 2004) at the HIV database website (http://
www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html).
Charge was calculated by counting all charged amino acid residues per
sequence, where R and K were counted as+1, H as+0.293, and D and
E as−1.
Statistical analysis
Statistical analyses were performed in SPSS 16 software package.
Longitudinal changes in sensitivity to anti-CCR5 MAbs RoAb13 and
RoAb952, in charge and PSSM score of the gp120 V3 region and in the
number of PNGS in gp120 C1–V5, were assessed using a Kruskal–Wallis
test. Differences in sensitivity to anti-CCR5MAbs RoAb13 and RoAb952,
in charge and PSSM score of the gp120 V3 region and in number of
PNGS in gp120 C1–V5, between two different time points were evaluat-
ed using the Mann–Withney U test.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.10.005.
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